
Quarterly report 2024-Q3
added 11-07-2024
Avinger Net Debt 2011-2026 | AVGR
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Avinger
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -16.3 M | -9.2 M | 2.88 M | -8.92 M | 39.4 M | 46.5 M | -13.5 M | 16.7 M | 21.6 M | -20.6 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.5 M | -20.6 M | 5.85 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
-925 M | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
15.2 M | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 24.4 | 2.61 % | $ 206 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.17 | 1.1 % | $ 260 M | ||
|
Globus Medical
GMED
|
-511 M | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.14 | 2.22 % | $ 876 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.37 | -0.88 % | $ 126 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.85 | 1.86 % | $ 353 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 36.59 | 5.94 % | $ 1.14 B | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.62 | 0.22 % | $ 122 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.71 | 1.08 % | $ 47.8 B | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Varex Imaging Corporation
VREX
|
225 M | $ 11.04 | 4.25 % | $ 457 M | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.88 | 2.73 % | $ 1.14 M | ||
|
Inogen
INGN
|
-86.3 M | $ 6.67 | -1.91 % | $ 177 M | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.01 | 1.59 % | $ 376 M |